Could a common diabetes drug shield your brain from stroke and dementia?
NCT ID NCT05356104
First seen Mar 07, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tests whether a GLP-1 drug (a type of diabetes medication) can prevent the progression of cerebral small vessel disease, a condition that damages tiny blood vessels in the brain and can lead to stroke, dementia, and mobility issues. About 110 Chinese adults aged 55–80 with moderate-to-severe disease will receive the drug or a placebo. The goal is to see if the drug can protect brain function and reduce the risk of further strokes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL SMALL VESSEL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese University of Hong Kong
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.